<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36412057</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>95</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J Med Virol</ISOAbbreviation></Journal><ArticleTitle>Clinical features, therapeutic outcomes, and recovery period of long COVID.</ArticleTitle><Pagination><StartPage>e28316</StartPage><MedlinePgn>e28316</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e28316</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.28316</ELocationID><Abstract><AbstractText>To characterize the clinical features of long COVID, 286 patients who received care in our outpatient clinic for long COVID from May to December 2021 were surveyed. The recovery periods of each symptom and the key factors contributing to early recovery were statistically analysed. The median age of the patients was 35.8 years, with 137 men and 149 women. The median number of symptoms was 2.8. The most frequent symptoms were respiratory manifestations (52.1%), followed by fatigue (51.4%). Respiratory symptoms, fatigue, and headache/arthralgia were major complaints in the initial phase, whereas hair loss was a major complaint in the late phase, suggesting that the chief complaint of patients with long COVID may vary temporally. The best treatment outcome was observed for pulmonary symptoms, and hair loss had the worst outcome. COVID-19 severity, the number of manifestations, and the delay in starting treatment exerted a negative effect on the recovery period of long COVID. In addition, the smoking habit was an independent risk factor for slowing the recovery period from long COVID. This study provides insights into the clinical course of each manifestation and therapeutic options with a more certain future of long COVID to meet the unmet medical needs.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Takakura</LastName><ForeName>Kazuki</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-1444-3761</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, UnMed Clinic Motomachi, Yokohama, Kanagawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suka</LastName><ForeName>Machi</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2125-2218</Identifier><AffiliationInfo><Affiliation>Department of Public Health and Environmental Medicine, The Jikei University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kajihara</LastName><ForeName>Mikio</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-3316-1121</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Kajihara Clinic, Hiratsuka, Kanagawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koido</LastName><ForeName>Shigeo</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0397-4348</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine,&#xa0;Division of Gastroenterology and Hepatology, The Jikei University Kashiwa Hospital, Chiba, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">herbaceous medication</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">multisystem disorder</Keyword><Keyword MajorTopicYN="N">persistent symptoms</Keyword><Keyword MajorTopicYN="N">recovery period</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>22</Day><Hour>3</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36412057</ArticleId><ArticleId IdType="pmc">PMC10108287</ArticleId><ArticleId IdType="doi">10.1002/jmv.28316</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Carf&#xec; A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID&#x2010;19. JAMA. 2020;324(6):603&#x2010;605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde MW, Kim SS, Lindsell CJ, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID&#x2010;19 in a multistate health care systems network&#x2014;United States, March&#x2013;June 2020. MMWR Morb Mortal Wkly Rep. 2020;69(30):993&#x2010;998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7392393</ArticleId><ArticleId IdType="pubmed">32730238</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyazato Y, Morioka S, Tsuzuki S, et al. Prolonged and late&#x2010;onset symptoms of coronavirus disease 2019. Open Forum Infect Dis. 2020;7(11):ofaa507.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7665672</ArticleId><ArticleId IdType="pubmed">33230486</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, et al. 6&#x2010;month consequences of COVID&#x2010;19 in patients discharged from hospital: a cohort study. The Lancet. 2021;397(10270):220&#x2010;232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah W, Hillman T, Playford ED, Hishmeh L. Managing the long term effects of covid&#x2010;19: summary of NICE, SIGN, and RCGP rapid guideline. BMJ. 2021;372:n136.</Citation><ArticleIdList><ArticleId IdType="pubmed">33483331</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post&#x2010;acute covid&#x2010;19 in primary care. BMJ. 2020;370:m3026.</Citation><ArticleIdList><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta SD, Talwar A, Lee JT. A proposed framework and timeline of the spectrum of disease due to SARS&#x2010;CoV&#x2010;2 infection: illness beyond acute infection and public health implications. JAMA. 2020;324(22):2251&#x2010;2252.</Citation><ArticleIdList><ArticleId IdType="pubmed">33206133</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al. Post&#x2010;acute COVID&#x2010;19 syndrome. Nature Med. 2021;27(4):601&#x2010;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of Long&#x2010;COVID: analysis of COVID cases and their symptoms collected by the Covid symptoms study app. medRxiv. 2020.</Citation></Reference><Reference><Citation>Bai F, Tomasoni D, Falcinella C, et al. Female gender is associated with long COVID syndrome: a prospective cohort study. Clin Microbiol Infect. 2021;28:611.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8575536</ArticleId><ArticleId IdType="pubmed">34763058</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nature Med. 2021;27(4):626&#x2010;631.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>F&#xf6;rster C, Colombo MG, Wetzel AJ, Martus P, Joos S. Persisting symptoms after COVID&#x2010;19&#x2014;prevalence and risk factors in a population&#x2010;based cohort. Dtsch Arztebl Int. 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9215272</ArticleId><ArticleId IdType="pubmed">35236547</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaksi N, Teker AG, Imre A. Long COVID in hospitalized COVID&#x2010;19 patients: a retrospective cohort study. Iran J Public Health. 2022;51(1):88&#x2010;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8837882</ArticleId><ArticleId IdType="pubmed">35223629</ArticleId></ArticleIdList></Reference><Reference><Citation>Righi E, Mirandola M, Mazzaferri F, et al. Determinants of persistence of symptoms and impact on physical and mental wellbeing in long COVID: a prospective cohort study. J Infect. 2022;84:566&#x2010;572.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8828388</ArticleId><ArticleId IdType="pubmed">35150765</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogawa&#x2010;Ochiai K, Ishikawa H, Li H, et al. Immunological and preventive effects of hochuekkito and kakkonto against coronavirus disease in healthcare workers: a retrospective observational study. Front Pharmacol. 2021;12:766402.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8636833</ArticleId><ArticleId IdType="pubmed">34867392</ArticleId></ArticleIdList></Reference><Reference><Citation>Noda T, Shiga H, Yamada K, et al. Effects of tokishakuyakusan on regeneration of murine olfactory neurons in vivo and in vitro. Chem Senses. 2019;44(5):327&#x2010;338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6538963</ArticleId><ArticleId IdType="pubmed">30989168</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogawa T, Nakamura K, Yamamoto S, Tojima I, Shimizu T. Recovery over time and prognostic factors in treated patients with post&#x2010;infectious olfactory dysfunction: a retrospective study. Ann Otol, Rhinol, Laryngol. 2020;129(10):977&#x2010;982.</Citation><ArticleIdList><ArticleId IdType="pubmed">32456451</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuy I, Van Oudenhove L, Tack J. Review article: treatment options for functional dyspepsia. Aliment Pharmacol Ther. 2019;49(9):1134&#x2010;1172.</Citation><ArticleIdList><ArticleId IdType="pubmed">30924176</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding JH, Jin Z, Yang XX, et al. Role of gut microbiota via the gut&#x2010;liver&#x2010;brain axis in digestive diseases. World J Gastroenterol. 2020;26(40):6141&#x2010;6162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7596643</ArticleId><ArticleId IdType="pubmed">33177790</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramakrishnan S, Nicolau DV, Jr. , Langford B, et al. Inhaled budesonide in the treatment of early COVID&#x2010;19 (STOIC): a phase 2, open&#x2010;label, randomised controlled trial. Lancet Respiratory Medicine. 2021;9(7):763&#x2010;772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8040526</ArticleId><ArticleId IdType="pubmed">33844996</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawashima N, Hu X, Ishikawa N, Matsuhisa T, Sato J. A combination of herbal formulas, acupuncture, and novel pine&#x2010;needle stimulation for recurrent alopecia areata: a case report. Medicine. 2021;100(20):e26084.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8137033</ArticleId><ArticleId IdType="pubmed">34011130</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosn J, Piroth L, Epaulard O, et al. Persistent COVID&#x2010;19 symptoms are highly prevalent 6 months after hospitalization: results from a large prospective cohort. Clin Microbiol Infect. 2021;27(7):1041.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8107834</ArticleId><ArticleId IdType="pubmed">34125067</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez&#x2010;de&#x2010;las&#x2010;Pe&#xf1;as C, Guijarro C, Plaza&#x2010;Canteli S, Hern&#xe1;ndez&#x2010;Barrera V, Torres&#x2010;Macho J. Prevalence of post&#x2010;COVID&#x2010;19 cough one year after SARS&#x2010;CoV&#x2010;2 infection: a multicenter study. Lung. 2021;199(3):249&#x2010;253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8124095</ArticleId><ArticleId IdType="pubmed">33993321</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X, Liu X, Zhou Y, et al. 3&#x2010;month, 6&#x2010;month, 9&#x2010;month, and 12&#x2010;month respiratory outcomes in patients following COVID&#x2010;19&#x2010;related hospitalisation: a prospective study. Lancet Respiratory Medicine. 2021;9(7):747&#x2010;754.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8099316</ArticleId><ArticleId IdType="pubmed">33964245</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Yao Q, Gu X, et al. 1&#x2010;year outcomes in hospital survivors with COVID&#x2010;19: a longitudinal cohort study. The Lancet. 2021;398(10302):747&#x2010;758.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8389999</ArticleId><ArticleId IdType="pubmed">34454673</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y, Bitna&#x2010;Ha H, Kim SW, et al. Post&#x2010;acute COVID&#x2010;19 syndrome in patients after 12 months from COVID&#x2010;19 infection in Korea. BMC Infect Dis. 2022;22(1):93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8793328</ArticleId><ArticleId IdType="pubmed">35086489</ArticleId></ArticleIdList></Reference><Reference><Citation>Boglione L, Meli G, Poletti F, et al. Risk factors and incidence of long&#x2010;COVID syndrome in hospitalized patients: does remdesivir have a protective effect? QJM. 2022;114(12):865&#x2010;871.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8690187</ArticleId><ArticleId IdType="pubmed">34850210</ArticleId></ArticleIdList></Reference><Reference><Citation>Asadi&#x2010;Pooya AA, Akbari A, Emami A, et al. Risk factors associated with long COVID syndrome: a retrospective study. Iran J Med Sci. 2021;46(6):428&#x2010;436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8611223</ArticleId><ArticleId IdType="pubmed">34840383</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez&#x2010;de&#x2010;Las&#x2010;Pe&#xf1;as C, Pellicer&#x2010;Valero OJ, Navarro&#x2010;Pardo E, et al. Symptoms experienced at the acute phase of SARS&#x2010;CoV&#x2010;2 infection as risk factor of long&#x2010;term post&#x2010;COVID symptoms: the LONG&#x2010;COVID&#x2010;EXP&#x2010;CM multicenter study. Int J Infect Dis. 2022;116:241&#x2010;244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8743274</ArticleId><ArticleId IdType="pubmed">35017102</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy RK, Charles WN, Sklavounos A, Dutt A, Seed PT, Khajuria A. The effect of smoking on COVID&#x2010;19 severity: a systematic review and meta&#x2010;analysis. J Med Virol. 2021;93(2):1045&#x2010;1056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7436545</ArticleId><ArticleId IdType="pubmed">32749705</ArticleId></ArticleIdList></Reference><Reference><Citation>Patanavanich R, Glantz SA. Smoking is associated with COVID&#x2010;19 progression: a meta&#x2010;analysis. Nicotine Tob Res. 2020;22(9):1653&#x2010;1656.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7239135</ArticleId><ArticleId IdType="pubmed">32399563</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou H, Li Y, Zhang P, et al. Smoking is independently associated with an increased risk for COVID&#x2010;19 mortality: a systematic review and meta&#x2010;analysis based on adjusted effect estimates. Nicotine Tob Res. 2021;23(11):1947&#x2010;1951.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8244809</ArticleId><ArticleId IdType="pubmed">34049390</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerber LH, Weinstein AA, Mehta R, Younossi ZM. Importance of fatigue and its measurement in chronic liver disease. World J Gastroenterol. 2019;25(28):3669&#x2010;3683.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6676553</ArticleId><ArticleId IdType="pubmed">31391765</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim WR, Flamm SL, Di Bisceglie AM, Bodenheimer HC. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology. 2008;47(4):1363&#x2010;1370.</Citation><ArticleIdList><ArticleId IdType="pubmed">18366115</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S, Khan A. Clinical characteristics and outcomes of coronavirus disease 2019 among patients with preexisting liver disease in the United States: a multicenter research network study. Gastroenterology. 2020;159(2):768&#x2010;771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7196546</ArticleId><ArticleId IdType="pubmed">32376408</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen NN, Hoang VT, Dao TL, Dudouet P, Eldin C, Gautret P. Clinical patterns of somatic symptoms in patients suffering from post&#x2010;acute long COVID: a systematic review. Eur J Clin Microbiol Infect Dis. 2022;41:515&#x2010;545.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8830952</ArticleId><ArticleId IdType="pubmed">35142947</ArticleId></ArticleIdList></Reference><Reference><Citation>Deer RR, Rock MA, Vasilevsky N, et al. Characterizing long COVID: deep phenotype of a complex condition. EBioMedicine. 2021;74:103722.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8613500</ArticleId><ArticleId IdType="pubmed">34839263</ArticleId></ArticleIdList></Reference><Reference><Citation>Nune A, Durkowski V, Titman A, et al. Incidence and risk factors of long COVID in the UK: a single&#x2010;centre observational study. J R Coll Physicians Edinb. 2021;51(4):338&#x2010;343.</Citation><ArticleIdList><ArticleId IdType="pubmed">34882130</ArticleId></ArticleIdList></Reference><Reference><Citation>Douaud G, Lee S, Alfaro&#x2010;Almagro F, et al. SARS&#x2010;CoV&#x2010;2 is associated with changes in brain structure in UK Biobank. Nature. 2022;604:697&#x2010;707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9046077</ArticleId><ArticleId IdType="pubmed">35255491</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkens MTHM, Raafs AG, Verdonschot JAJ, et al. Age is the main determinant of COVID&#x2010;19 related in&#x2010;hospital mortality with minimal impact of pre&#x2010;existing comorbidities, a retrospective cohort study. BMC Geriatr. 2022;22(1):184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8897728</ArticleId><ArticleId IdType="pubmed">35247983</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashemi&#x2010;Shahri SM, Tabatabaei SMN, Ansari&#x2010;Moghaddam A, et al. Epidemiological and clinical risk factors related to severe COVID&#x2010;19 in Iran: a multi&#x2010;center study. BMC Infect Dis. 2022;22(1):184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8864589</ArticleId><ArticleId IdType="pubmed">35197013</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez&#x2010;de&#x2010;Las&#x2010;Pe&#xf1;as C, Mart&#xed;n&#x2010;Guerrero JD, Pellicer&#x2010;Valero &#xd3;J, et al. Female sex is a risk factor associated with long&#x2010;term post&#x2010;COVID related&#x2010;symptoms but not with COVID&#x2010;19 symptoms: the LONG&#x2010;COVID&#x2010;EXP&#x2010;CM multicenter study. J Clin Med. 2022;11(2):413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8778106</ArticleId><ArticleId IdType="pubmed">35054108</ArticleId></ArticleIdList></Reference><Reference><Citation>Tleyjeh IM, Saddik B, AlSwaidan N, et al. Prevalence and predictors of post&#x2010;acute COVID&#x2010;19 syndrome (PACS) after hospital discharge: a cohort study with 4 months median follow&#x2010;up. PLoS One. 2021;16(12):e0260568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8651136</ArticleId><ArticleId IdType="pubmed">34874962</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Nirantharakumar K, Hughes S, et al. Symptoms and risk factors for long COVID in non&#x2010;hospitalized adults. Nature Med. 2022;28:1706&#x2010;1714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuchida T, Hirose M, Inoue Y, Kunishima H, Otsubo T, Matsuda T. Relationship between changes in symptoms and antibody titers after a single vaccination in patients with long COVID. J Med Virol. 2022;94:3416&#x2010;3420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9088489</ArticleId><ArticleId IdType="pubmed">35238053</ArticleId></ArticleIdList></Reference><Reference><Citation>Al&#x2010;Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS&#x2010;CoV&#x2010;2 infection. Nature Med. 2022;28(7):1461&#x2010;1467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>